Summary Sera of 85 patients with benign soft tissue lesions or sarcomas of soft tissues were investigated for a collagen metabolite, the aminoterminal propeptide of type III procollagen (PIIINP). Patients were divided into three groups: benign soft tissue lesions (n = 39), localised (n = 29) and metastatic (n = 18) soft tissue sarcomas (STS). Values of PIIINP above the reference range were found in 15%, 28% and 50% of the respective groups. The difference in the concentration of PIIINP was statistically significant between the benign lesions and the localised sarcomas; P = 0.05, and between the benign lesions and the metastatic sarcomas; P < 0.001. In localised sarcomas there was a correlation between PIIINP and bone-involvement (r = 0.61, P = 0.002) and in metastatic disease between PIIINP and liver metastases (r=0.77, P<0.001). In localised sarcomas the overall survival for patients with a value of PIIINP above the reference range was significantly poorer (P = 0.03) than for patients with values within the reference range, even after stratification for the histological malignancy grade of the tumours (P = 0.04).
In malignant disease connective tissue metabolism may be involved in different mechanisms. The tumour may degrade matrix components in association with invasion, and there may be an increased production of matrix components by the host and/or by the tumour (Liotta et al., 1983) . Several methods have been developed that can be used to detect increased extracellular matrix metabolism in the body by a simple study of blood samples (Risteli & Risteli, 1989) . The assay for the aminoterminal propeptide of type III procollagen (PIIINP) has been commercially available and thus most often used. High levels of PIIINP have been found in patients with various cancers, particularly primary and secondary liver cancer (Bolarin et al., 1982) , but also in bone sarcomas (Elomaa et al., 1989a; Elomaa et al., 1989b) .
Type III collagen is found mainly in tissues such as skin, arteries and the uterus, muscle, liver and lung, bone marrow and periosteum (Prockop et al., 1979) . During synthesis of interstitial fibre-forming collagens (types I, II, III and V), procollagens with additional propeptide extensions at both ends of the molecule are formed first. These propeptides are cleaved off before the formation of collagen fibrils. The aminoterminal propeptides of type III procollagen are, however, not constantly cleaved off. Such type III collagen molecules which have retained the aminoterminal propeptides, called type III pN collagen, are usually found on the surface of collagen fibres (Fleischmajer et al., 1985) .
The propeptide is mainly eliminated by the liver endothelial cell (Smedsr0d, 1988) . Because its half-life in serum is only a few minutes, its presence indicates active collagen synthesis and turnover (Smedsr0d, 1988) . Quantification of the PIIINP antigen has been achieved by specific radioimmunoassays (Risteli et al., 1988a) . The antigen in serum is, however, heterogeneous, due to forms larger and smaller than the authentic propeptide (Niemeli et al., 1982) . The interference caused by the small degradation products of the propeptide has been successfully eliminated in the assay modification used in this study (Risteli et al., 1988a) . It is not known, however, whether the large PIIINP antigens are aggregates containing the authentic propeptide, or degradation products of tissue type III pN collagen (Niemela et al., 1982) .
The aim of the present study was to elaborate on whether there are differences in the serum concentration of PIIINP in patients with benign soft tissue lesions and soft tissue sarcomas (STS) of different stages, and to study whether the propeptide level could be correlated with any clinical findings or used as a prognostic marker.
Materials and methods

Patients
The material studied consists of all the patients attending Helsinki University Central Hospital for a verified or suspected non-osseous sarcoma between May 1988 and October 1990. Samples from patients with benign lesions and sarcomas without evidence of metastases at time of sampling were taken preoperatively and from patients with metastatic sarcomas before surgery was performed or chemotherapy started. Excluded were patients under the age of 16 years, patients operated on within 1 year before sampling (with the exception of patients having minor incision biopsies), and patients who had received chemotherapy within 1 year before sampling.
Eighty-six samples from 85 patients met our inclusion criteria. These were divided into three groups; patients with benign soft tissue lesions of the trunk and the extremities (n = 39), patients with sarcomas without evidence of metastases at the time of sampling (n = 29) and patients with metastases present at the time of sampling (n = 18). Seven localised and 40 metastatic sarcomas were excluded because of recent surgery or chemotherapy. In the analysis local recurrences were regarded as new primaries. In each group, however, each patient was included only once. All tumours were histologically confirmed with the exception of a few benign lesions whose benign nature were judged on clinical or radiological grounds. Tumours were histologically graded using a four-graded scale (Markhede et al., 1982) . In the analysis high grade tumours were those of malignancy grade three and four, and low grade tumours those of grade one and two.
Fourteen of the benign lesions were lipomas, five neurilemomas, three elastofibromas and two desmoid tumours, hemangiomas and myositis ossificans each. Eleven were miscellaneous soft tissue lesions or tumours, one of each.
The histological subtypes of the sarcomas are presented in Other diseases which might affect the connective tissue metabolism were recorded from the hospital records. Two patients had severe osteoarthritis of the knee joint, and six patients had elevated liver enzymes (patients with liver metastases excluded).
Radioimmunoassays
The concentration of PIIINP was analysed with an equilibrium type of radioimmunoassay (Risteli et al., 1988a ) based on a human antigen (Farmos Diagnostica, SF-90460 Oulunsalo, Finland), using 200 tl aliquots of serum. The assay detects the authentic propeptide and another, somewhat larger related antigen, but it is not sensitive to the smaller degradation products of the propeptide. In this assay modification the standards and serum samples give parallel inhibition curves. The intra-and interassays coefficients of variation of the method are about 5% (Risteli et al., 1988a) .
Serum was stored at -20°C until analysed. The reference range of PIIINP among adult Finnish blood donors is 1.7-4.2 jig I' (mean ± 2 s.d.) (Risteli et al., 1988a (> 7.0 .tg 1-1) were found in three patients with extensive metastatic lesions in the liver. Three out of four patients with liver metastases had markedly elevated liver function tests. Two patients had elevated liver function tests without liver metastases, one of these had an elevated PIIINP level. When the value of PIIINP was tested for each metastatic site there was a significant positive linear correlation between the presence of liver metastases (r = 0.77, P<0.001) and a value of Time (years) Figure 2 Overall survival for patients with a initially elevated value of PIIINP (>4.2ftgl-') (*) and patients with PIIINP within the reference range (<4.2p1g -') (O).
PIIINP above the reference range. No other metastatic site (lung, bone, multiple) (Bolarin et al., 1982; Risteli et al., 1988c; Toma's et al., 1990b; Blomqvist et al., 1987) . In follow-up studies on ovarian cancer the level of PIIINP follows the clinical behaviour and the level of CA-125 (Tomfas et al., 1990a) . In previous studies by us on sarcomas of bone, the antigen appears to be a good indicator of the clinical behaviour of the disease (Elomaa et al., 1989a; Elomaa et al., 1989b) .
Several conditions other than malignancies that elevate the level of PIIINP have been identified, including normal growth and pregnancy, as well as rheumatoid arthritis and osteoarthritis (Risteli et al., 1988a; Risteli et al., 1987; H0rs-lev-Petersen et al., 1988) . During normal and pathological wound healing after moderate to major surgery there is a marked elevation of the level of PIIINP with a maximum within 30 days postoperatively and a slow decrease. Slightly higher levels than the preoperative can be detected up to half a year postoperatively (Haukipuro et al., 1990) . High levels are also detected in various liver diseases, as during longterm low dose chemotherapy with methotrexate for psoriasis (Risteli et al., 1988b) .
In this first cross-sectional report on PIIINP in benign soft tissue lesions and soft tissue sarcomas we have, on the basis of previous literature, excluded possible confounding effects of surgery or chemotherapy on the level of PIIINP in an attempt to discriminate the unmasked effect of the tumour on the collagen metabolism. No data on the effect of radiotherapy on the serum level of PIIINP are currently available, however, only one of our patients with a metastatic sarcoma had recently received radiotherapy. In eight patients conditions known to affect the collagen metabolism were present (i.e. rheumatoid arthritis, osteoarthritis and liver disease). (Smedsr0d, 1988 
